Sugi Predict

Sugi Predict / Compounds / SCHEMBL356806

SCHEMBL356806

SCHEMBL356806

CCC(CC)OC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL9 O00512 1/20 0.57
▸ CTNNB1 P35222 1/20 0.57
▸ HTR2A P28223 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ MGLL Q99685 2/20 0.51
▸ MAPT P10636 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ CRHBP P24387 1/20 0.45
▸ CRHR2 Q13324 1/20 0.45
▸ MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27108049 0.92 BCL9 (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL29830631 0.88 BCL9 (0.58) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL1721472 0.88 MGLL (0.54) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL30668164 0.87 MGLL (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL12375535 0.87 BCL9 (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL21097204 0.87 BCL9 (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL21097658 0.87 BCL9 (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL26976971 0.86 MGLL (0.56) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL30232724 0.85 BCL9 (0.51) BCL9CTNNB1HTR2AGAAMGLL
SCHEMBL356819 0.85 BCL9 (0.50) BCL9CTNNB1HTR2AGAAMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors UNIVERSITY OF MASSACHUSETTS (US) 2025-10-14 — — US disclosed
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 — — EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 — — CN disclosed
US-20240182510-A1 Compounds Useful in HIV Treatment VIIV HEALTHCARE COMPANY (US) 2024-06-06 — — US disclosed
EP-4298105-A1 COMPOUNDS USEFUL IN HIV TREATMENT VIIV Healthcare Company (US) 2024-01-03 — — EP disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed
WO-2022182604-A1 COMPOUNDS USEFUL IN HIV TREATMENT VIIV HEALTHCARE COMPANY (US) 2022-09-01 — — WO disclosed
US-20220227806-A1 HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS UNIV MASSACHUSETTS (US) 2022-07-21 — — US disclosed
WO-2020247736-A1 HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS UNIVERSITY OF MASSACHUSETTS (US) 2020-12-10 — — WO disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 — — US disclosed
WO-2010084944-A1 NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND 田辺三菱製薬株式会社 (JP) 2010-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 BCL9 1839/4885CTNNB1 2154/4885HTR2A 624/4885
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors HAVCR2, CTSC, DPP4 BCL9 807/4885CTNNB1 1528/4885HTR2A 3305/4885
US-20220227806-A1 HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS HAVCR2, CTSC, DPP4 BCL9 807/4885CTNNB1 1528/4885HTR2A 3305/4885
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA BCL9 1422/4885CTNNB1 3190/4885HTR2A 1950/4885
US-20240182510-A1 Compounds Useful in HIV Treatment CCR5, G6PD, NPC1 BCL9 1739/4885CTNNB1 4112/4885HTR2A 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.